Literature DB >> 35217973

Organ-Specific Adverse Effects After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Rogini Balachandran1,2,3, Louise Zinck Mogensen4, Peter Christensen4,5,6, Henriette Vind Thaysen4,5, Lene Hjerrild Iversen4,5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35217973     DOI： 10.1245/s10434-022-11356-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   4.339


× No keyword cloud information.
  56 in total

1.  Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Authors:  A Gómez Portilla; P Barrios; S Rufian; B Camps; P Bretcha; L Gonzalez Bayon; J Torres Melero; M García Polavieja; S Gonzalez Moreno
Journal:  Eur J Surg Oncol       Date:  2006-05-08       Impact factor: 4.424

Review 2.  Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality.

Authors:  Terence C Chua; Tristan D Yan; Akshat Saxena; David L Morris
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

Review 3.  Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.

Authors:  V Narasimhan; S Tan; J Kong; T Pham; M Michael; R Ramsay; S Warrier; A Heriot
Journal:  Colorectal Dis       Date:  2020-02-27       Impact factor: 3.788

4.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Authors:  Jan Franko; Qian Shi; Jeffrey P Meyers; Timothy S Maughan; Richard A Adams; Matthew T Seymour; Leonard Saltz; Cornelis J A Punt; Miriam Koopman; Christophe Tournigand; Niall C Tebbutt; Eduardo Diaz-Rubio; John Souglakos; Alfredo Falcone; Benoist Chibaudel; Volker Heinemann; Joseph Moen; Aimery De Gramont; Daniel J Sargent; Axel Grothey
Journal:  Lancet Oncol       Date:  2016-10-12       Impact factor: 41.316

5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.

Authors:  L H Iversen; P C Rasmussen; R Hagemann-Madsen; S Laurberg
Journal:  Colorectal Dis       Date:  2013-07       Impact factor: 3.788

6.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

7.  Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.

Authors:  B L van Leeuwen; W Graf; L Pahlman; H Mahteme
Journal:  Ann Surg Oncol       Date:  2007-12-05       Impact factor: 5.344

8.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08

9.  Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Authors:  R Mirnezami; A M Mehta; K Chandrakumaran; T Cecil; B J Moran; N Carr; V J Verwaal; F Mohamed; A H Mirnezami
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

10.  Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Maleen Leimkühler; Judith E K R Hentzen; Patrick H J Hemmer; Lukas B Been; Robert J van Ginkel; Schelto Kruijff; Barbara L van Leeuwen; Geertruida H de Bock
Journal:  Ann Surg Oncol       Date:  2020-04-26       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.